Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average of $1.98

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.98 and traded as high as $1.98. Inovio Pharmaceuticals shares last traded at $1.90, with a volume of 245,336 shares.

Analyst Ratings Changes

A number of research analysts recently commented on INO shares. Bank of America lowered shares of Inovio Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $2.00 price objective on the stock. in a research note on Tuesday, November 1st. StockNews.com upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, December 19th. Finally, Maxim Group cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

Inovio Pharmaceuticals Stock Down 0.5 %

The company has a debt-to-equity ratio of 0.06, a current ratio of 3.69 and a quick ratio of 3.69. The firm has a market capitalization of $474.03 million, a P/E ratio of -1.29 and a beta of 1.08. The business has a 50 day moving average price of $1.86 and a 200 day moving average price of $1.98.

Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. Inovio Pharmaceuticals had a negative return on equity of 100.75% and a negative net margin of 3,027.10%. The company had revenue of $9.15 million during the quarter, compared to the consensus estimate of $0.53 million. During the same quarter last year, the company earned ($0.29) EPS. The company’s quarterly revenue was up 3034.9% on a year-over-year basis. On average, analysts predict that Inovio Pharmaceuticals, Inc. will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of INO. TIAA FSB acquired a new position in Inovio Pharmaceuticals in the second quarter valued at about $25,000. Metropolitan Life Insurance Co NY raised its holdings in Inovio Pharmaceuticals by 88.5% in the third quarter. Metropolitan Life Insurance Co NY now owns 14,957 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 7,023 shares during the period. Great West Life Assurance Co. Can bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth $28,000. Keebeck Alpha LP bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth $29,000. Finally, Walker Asset Management LLC acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $29,000. Institutional investors own 46.44% of the company’s stock.

Inovio Pharmaceuticals Company Profile

(Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.